Form 8-K ARVINAS, INC. For: Jun 11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities climb as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazil’s Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Oil settles lower on peace hopes, Saudi attacks limit losses
- Britain will not join Canada-led defence bank initiative
Arvinas and Pfizer complete Rigel license deal for vepdegestrant
June 16, 2026 4:33 PM EDTArvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. have completed a license agreement with Rigel Pharmaceuticals, Inc., granting Rigel exclusive global rights to develop, manufacture, and commercialize VEPPANU (vepdegestrant), according to a company statement.
The transaction received early termination of the Hart-Scott-Rodino antitrust waiting... More



